

CLAIMS

1. An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - (a) sequences provided in SEQ ID NO:1865-1868, 1873, 1883, 1884-1890, 1910;
 - (b) complements of the sequences provided in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890;
 - (c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890;
 - (d) sequences that hybridize to a sequence provided in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890, under moderately stringent conditions;
 - (e) sequences having at least 75% identity to a sequence of SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890;
 - (f) sequences having at least 90% identity to a sequence of SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890; and
 - (g) degenerate variants of a sequence provided in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890.
2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) SEQ ID NO:1869-1872 and 1874;
 - (b) sequences encoded by a polynucleotide of claim 1;
 - (c) sequences having at least 70% identity to a sequence encoded by a polynucleotide of claim 1; and
 - (d) sequences having at least 90% identity to a sequence encoded by a polynucleotide of claim 1.

3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence.
4. A host cell transformed or transfected with an expression vector according to claim 3.
5. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2.
6. A method for detecting the presence of a cancer in a patient, comprising the steps of:
 - (a) obtaining a biological sample from the patient;
 - (b) contacting the biological sample with a binding agent that binds to a polypeptide of claim 2;
 - (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and
 - (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient.
7. A fusion protein comprising at least one polypeptide according to claim 2.
8. An oligonucleotide that hybridizes to a sequence recited in SEQ ID NO:1865-1868, 1873, 1883 and 1884-1890 under moderately stringent conditions.
9. A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:
 - (a) polypeptides according to claim 2;

- (b) polynucleotides according to claim 1; and
- (c) antigen-presenting cells that express a polypeptide according to claim 2,

under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

10. An isolated T cell population, comprising T cells prepared according to the method of claim 9.

11. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of:

- (a) polypeptides according to claim 2;
- (b) polynucleotides according to claim 1;
- (c) polynucleotides having a sequence as provided in SEQ ID NO:1910;
- (d) antibodies according to claim 5;
- (e) fusion proteins according to claim 7;
- (f) T cell populations according to claim 10; and
- (g) antigen presenting cells that express a polypeptide according to claim

2

12. A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim 11.

13. A method for the treatment of a cancer in a patient, comprising administering to the patient a composition of claim 11.

18. The fusion protein of claim 7, wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO:1876, 1873, 1913, 1917 and 1921.